ALEXANDER JACOBSON: Open Payments
NPI 1639199169 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$850 in 26 payments from 10 companies in 2025. Trend: 2023 $618 · 2024 $733 · 2025 $850
Food & beverage: $850
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $239 |
| Janssen Pharmaceuticals, Inc | 3 | $156 |
| E.R. Squibb & Sons, L.L.C. | 3 | $114 |
| Axsome Therapeutics, Inc. | 4 | $93 |
| Lundbeck LLC | 3 | $70 |
| Indivior Inc. | 1 | $61 |
| Alkermes, Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Vanda Pharmaceuticals Inc. | 1 | $19 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
Products named: CAPLYTA, INVEGA SUSTENNA, COBENFY, Auvelity, REXULTI, SUBLOCADE, ARISTADA, UZEDY.
Industry payments across DE — which companies pay providers there.
